

Ref: FOI/GS/ID 8560

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

02 November 2023

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Breast cancer.

You asked:

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- a. Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)*
- b. Abemaciclib + Fulvestrant*
- c. Alpelisib + Fulvestrant*
- d. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent*
- e. Atezolizumab + Nab-paclitaxel/Paclitaxel*
- f. Capecitabine as a single agent*
- g. Eribulin as a single agent or in combination*
- h. Everolimus + Exemestane*
- i. Fulvestrant as a single agent*
- j. Lapatinib*
- k. Neratinib*
- l. Parp Inhibitors (Olaparib/Talazoparib)*
- m. Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)*
- n. Palbociclib + Fulvestrant*
- o. Pembrolizumab*
- p. Platinum (e.g. carboplatin or cisplatin) as a single agent*
- q. Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)*
- r. Ribociclib + Fulvestrant*
- s. Sacituzumab Govitecan*
- t. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent*
- u. Taxane and/or Anthracycline in combination*
- v. Trastuzumab as a single agent or in combination*
- w. Trastuzumab emtansine*

x. *Transtuzumab deruxtecan*

y. *Any other active systemic anti-cancer therapy*

Trust response:

Q1	
a.	29
b.	1
c.	0
d.	5
e.	9
f.	28
g.	3
h.	7
i.	0
j.	0
k.	0
l.	0
m.	63
n.	21
o.	3
p.	2
q.	12
r.	6
s.	2
t.	22
u.	42
v.	94
w.	12
x.	2
y.	2